A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023-2024 rose 84.6% in Gen Alpha (ages 14 and younger). The age group was ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4% in 2022. As a result, annual spending jumped from $1.6 billion to $5. ...

The pioneering Yellow Card Biobank, launched by the Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics ...

While GLP-1 use may be temporary, the mindset shift is likely long-term. Consumers who start their weight loss journey with these medications are developing new habits and looking for products to ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

In a matched group of more than 170,000 adults, those treated with GLP-1 agonists had a lower risk of developing an obesity-related cancer over a median follow-up of about 4 years when compared ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Sai Lomte, Tarun. (2025, May 14). GLP-1 weight loss drugs leave users low on key nutrients, study ...

DENVER, April 04, 2025--Virta Health, a leader in diabetes reversal and sustainable weight loss with a nutrition-first approach, announced early and compelling results from its Sustainable Weight ...

This new study was prospective, meaning the researchers proactively tracked how people’s alcohol use changed after starting GLP-1 therapy (many past similar studies were retrospective, which ...

Over three years of follow-up between 2020 and 2023, 0.2% (93 patients) of those in the GLP-1 user group were diagnosed with nAMD, as were 0.1% (88 patients) in the contrasting group.